Celgene Rising On Positive Data from Pipeline Product

Celgene Corp (CELG) announced late on Wednesday that data from its phase 2 clinical study of REVLIMID was published in the New England Journal of Medicine.

REVLIMID is an immunomodulatory agent being studied in patients with myelodysplastic syndromes [MDS]. MDS are a group of malignancies affecting hematopoietic stem cells, the immature blood cells of the bone marrow. Patients affected will exhibit a high number of immature blood cells, and a low concentration of mature red blood cells.

In the current phase 2 study REVLIMID showed a hematologic response, and a high level of cytogenetic activity.

Shares of Celgene ended trading on Wednesday up more than 5% at $44.51.